novo nordisk chronic kidney disease

Novo Nordisk’s Ozempic Gets FDA Approval

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

Medscape · 1d

Ozempic Receives New Indications in Chronic Kidney Disease

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.

Bloomberg on MSN · 1d

Novo’s Ozempic Gains US Nod for Kidney Disease, Widening Use

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.

Renal & Urology News15h

KDIGO Issues New ADPKD Guideline

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

15h

Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk’s Ozempic Gets FDA Approval

Trending now